| Company Name | Bayer Taiwan Co., Ltd. |
|---|---|
| Protocol Number | 21785 |
| Title of Study | FINE-REAL: A non-interventional study providing insights into the use of finerenone in a routine clinical setting |
| Primary Objective | The aim of this study is to provide insights on characteristics and treatment patterns of participant with CKD and T2D treated with finerenone in routine clinical practice. The primary objective in this study is to describe clinical characteristics of and treatment patterns in participants with CKD and T2D treated with finerenone in routine clinical practice. |
| Number of Sites | 10 |
| Period of Study | From：2023/11/28 to：2028/06/01 |
| Number of Patients | 150人 |
| IRB Approval Date | CMMC: 2023/09/14 NCKUH: 2023/11/24 NTUH: 2023/10/20 FEMH: 2023/10/28 TSGH: 2023/09/07 SHH: 2023/10/16 CGMHLK: 2023/12/1 KMUH: Pending for IRB approval 游新診所: Pending for IRB approval 陳宏麟診所: Pending for IRB approval |
| Publication Plan / Date | After 2028/06/01 |
